Zargar, Homayoun <br/><br/>
Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer.  [electronic resource] 

 -  European urology  Feb 2015 
 - 241-9 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1873-7560 
<br/><br/><label>Standard No.: </label>10.1016/j.eururo.2014.09.007  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Chemotherapy, Adjuvant<br/>Cisplatin--therapeutic use<br/>Cystectomy<br/>Deoxycytidine--analogs & derivatives<br/>Doxorubicin--therapeutic use<br/>Europe<br/>Female<br/>Humans<br/>Male<br/>Methotrexate--therapeutic use<br/>Middle Aged<br/>Multivariate Analysis<br/>Neoadjuvant Therapy--adverse effects<br/>Neoplasm Invasiveness<br/>Neoplasm Staging<br/>North America<br/>Odds Ratio<br/>Proportional Hazards Models<br/>Retrospective Studies<br/>Time Factors<br/>Treatment Outcome<br/>Urinary Bladder Neoplasms--drug therapy<br/>Vinblastine--therapeutic use<br/>Gemcitabine